The DOI matches its Crossref record.
REM sleep and central monoamine oxidase inhibition
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
REM rebound is noted subsequent to the withdrawal of MAOI medication.
“However, REM rebound is noted subsequent to the withdrawal of medication (Kupfer and Bowers Jr, 1972).”
From Antidepressants and their effect on sleep (2005) · cites this paper as Kupfer and Bowers Jr, 1972
PSG studies have confirmed a tendency for prolonged sleep latency and impaired sleep continuity associated with increased awakenings and increased WASO in patients treated with MAOIs.
“PSG studies have confirmed a tendency for prolonged sleep latency and impaired sleep continuity associated with increased awakenings and increased WASO in patients being treated with these compounds [Wyatt et al., 1971;Kupfer and Bowers, 1972].”
From Depression, sleep physiology, and antidepressant drugs (2001) · cites this paper as Kupfer and Bowers, 1972
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 19
- Aghajanian, G. K., Graham, A. W., Sheard, M. H.: Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors. Science 169, 1100–1102 (1970). · DOI
- Akindele, M. O., Evans, J. I., Oswalk, I.: Monoamine oxidase inhibitors, sleep, and mood. Electroenceph. clin. Neurophysiol. 29, 47–56 (1970). · DOI
- Ashcroft, G. W., Crawford, T. B. B., Dow, R. C., Moir, A. T. B.: Release of amine metabolite into ventricular perfusion fluid as an index of turnover. In: Metabolism of amines in the brain. G. Hooper London: Macmillian 1969.
- Bevan Jones, A. B., Pare, C. M. B., Nicholson, W. J., Price, K., Stacey, R. S.: Brain amine concentrations after monoamine oxidase inhibitor administration. Brit. med. J. 1972 I, 17–19. · DOI
- Bowers, M. B., Jr.: Clinical measurements of central dopamine 5-hydroxytryptamine metabolism. Neuropharmacology 11, 101–111 (1972a). · DOI
- Bowers, M. B., Jr.: Cerebrospinal fluid 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) following probenecid in unipolar depressives treated with amitriptyline. Psychopharmacologia (Berl.) 23, 26–33 (1972b). · DOI
- Bowers, M. B., Jr., Kupfer, D. J.: Central monoamine oxidase inhibition and REM sleep. Brain Res. 35, 561–564 (1971). · DOI
- Forn, J., Mailing, H. M., Gessa, G. L.: Homovanillic and 5-hydroxyindoleacetic acids in cerebrospinal fluid after probenecid: Measurement of brain monoamine oxidase inhibition in vivo. Proc. Soc. exp. Biol. (N.Y.) 133, 1310–1313 (1970). · DOI
- Hartmann, E., Chung, R., Draskoczy, P. R., Schildkraut, J. J.: Effects of 6-hydroxydopamine on sleep in the rat. Nature (Lond.) 233, 425–427 (1971). · DOI
- Himmelhoch, J. M., Detre, T. P., Kupfer, D. J., Swartzburg, M., Byck, R.: Treatment of previously-intractable depressions with tranylcypromine and lithium. J. nerv. ment. Dis. 155, 216–220 (1972). · DOI
- Jouvet, M.: Mechanisms of the states of sleep: A neuropharmacological approach. Res. Publ. Ass. nerv. ment. Dis. 45, 86–126 (1967).
- Klein, D. F., Davis, J. M.: Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins 1969.
- Kupfer, D. J., Foster, F. G.: Sleep and activity in a psychotic depression. J. nerv. ment Dis. (in press).
- Kupfer, D. J., Foster, F. G., Bowers, M. B., Jr.: Selective suppression of REM sleep by probenecid. Brain Res. 41, 205–210 (1972). · DOI
- Pare, C. M. M., Rees, L., Sainsbury, M. S.: Differences of two genetically specific types of depression by the response to antidepressants. Lancet 1962, 1340–1343. · DOI
- Rechtschaffen, A., Kales, A. A.: A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. Bethesda, Maryland: N.I.N.D.B. 1968.
- Van Praag, H. M., Korf, J.: Retarded depression and the dopamine metabolism. Psychopharmacologia (Berl.) 19, 199–203 (1971). · DOI
- Wyatt, R. J., Chase, T. N., Kupfer, D. J., Scott, J., Snyder, F., Sjoerdsma, A., Engelman, K.: Brain catecholamines and human sleep. Nature (Lond.) 233, 63–64 (1971). · DOI
- Wyatt, R. J., Fram, D. H., Kupfer, D. J., Snyder, F.: Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch. gen. Psychiat. 24, 145–155 (1971a). · DOI · Paper page
Cited by
Sorted by citations
The reinterpretation of dreams: An evolutionary hypothesis of the function of dreaming
Revonsuo, A. (2000) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00004015 · Cited by 676
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323
Depression, sleep physiology, and antidepressant drugs
Winokur, A., Gary, K. A., Rodner, S., Rae-Red, C., Fernando, A. T., & Szuba, M. P. (2001) · Depression and Anxiety · doi:10.1002/da.1043 · Cited by 179
Tribl, G. G., Wetter, T. C., & Schredl, M. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.05.001 · Cited by 76
Metadata
- Authors
- Kupfer, D. J., & Bowers, M. B.
- Affiliations
- Yale University (US)
- ORCID
- Kupfer, David J.
- Venue
- Psychopharmacologia
- Published
- 1972-09
- Volume
- 27
- Issue
- 3
- Pages
- 183-190
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1978301558
- Cited by
- 76
- References
- 0
- Citations by year
- 2019: 2 · 2016: 2 · 2012: 2
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- REM sleep, monoamine oxidase inhibition, phenelzine, lumbar cerebrospinal fluid, homovanillic acid, 5-hydroxyindoleacetic acid, dopamine, catecholamines, REM rebound, drug withdrawal, antidepressant side effects
- MeSH terms
- Adolescent, Adult, Blood-Brain Barrier, Brain, Depression, Electroencephalography, Female, Humans, Hydroxyindoleacetic Acid, Male, Middle Aged, Phenelzine, Phenylacetates, Probenecid, Sleep, REM
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
